Prescribing information


What is Sandostatin® LAR® (octreotide acetate) used for?


SANDOSTATIN LAR is indicated for the treatment of:

  • Patients with symptoms associated with functional gastro-entero-pancreatic endocrine tumours (e.g. carcinoid tumours with features of the carcinoid syndrome) or patients with advanced neuroendocrine tumours of the midgut or of unknown primary origin where non-midgut sites of origin have been excluded.1
  • Patients with acromegaly in whom surgery is inappropriate or ineffective, or in the interim period until radiotherapy becomes fully effective.1
  • Patients with TSH-secreting pituitary adenomas:1
    • when secretion has not normalised after surgery and/or radiotherapy;
    • in patients in whom surgery is inappropriate;
    • in irradiated patients, until radiotherapy is effective.


Resources for you:


Preview image. Reconstitution and preparation of SANDOSTATIN LAR guide for HCPs.

Reconstitution and preparation of SANDOSTATIN LAR

A guide for HCPs on how to prepare and administer SANDOSTATIN LAR.




How to administer and prepare SANDOSTATIN LAR

A step-by-step video on how to prepare and administer SANDOSTATIN LAR.


Resources for your patients:


Preview image. Your guide to SANDOSTATIN LAR. Patient guide.


A guide for patients prescribed SANDOSTATIN LAR to help them understand the treatment options they may be offered.






  1. SANDOSTATIN® LAR® Summary of Product Characteristics.
Rate this content: 
Average: 2.7 (3 votes)
UK | August 2023 | 285829

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]